Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
351 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (3)
  • Closed (22)

Medical Condition

  • Show all (1900)
  • Addiction (16)
  • Allergy, Asthma, & Immunology (12)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (38)
  • Bone & Muscle (10)
  • Cancer (726)
  • Child Development (4)
  • COVID-19 (Coronavirus) (37)
  • Critical Illness (1)
  • Dental (2)
  • Developmental Disorders (2)
  • Diabetes (22)
  • Ear, Nose and Throat (11)
  • (-) Endocrine & Metabolic Disease (13)
    • Cushing's Disease (3)
    • Growth Hormone Deficiency (1)
  • Eye (8)
  • Gastrointestinal and Digestive Diseases (22)
  • Hair and Skin Disorders (2)
  • Headaches (5)
  • Healthy Volunteers (175)
  • Heart Disease (128)
  • Infectious Disease (48)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (48)
  • Lung Disease (32)
  • Meniere's Disease (1)
  • Neurological Disorders (174)
    • Alzheimer's Disease (37)
    • Brain Tumors (57)
    • Cerebral Palsy (3)
    • Dementia (8)
    • Huntington's Disease (4)
    • Multiple Sclerosis (8)
    • Neuromuscular (10)
    • (-) Neuropathy (12)
    • Parkinson's Disease (3)
  • Nutrition (4)
  • Obesity (9)
  • Obstetrics & Gynecology (51)
  • Pain Management (1)
  • Pediatrics (104)
  • Psychiatric Disorders (65)
  • Rehabilitation (8)
  • Stroke (7)
  • Surgery (7)
  • Transplant (51)
  • Urology (4)
  • Vascular Conditions (9)
Displaying 1 - 25 of 25

A Study to Test the Effects and Safety of Riliprubart in People with Chronic CIDP for Which the Usual Treatment Does Not Work

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Currently Recruiting
This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must…
Read More

Effect of lowering insulin levels on blood sugar

Condition: Endocrine & Metabolic Disease
Investigator: Joshua Cook, MD, PhD
Status: Currently Recruiting
We are conducting a research study on how insulin controls blood sugar in both healthy people and those at risk of type 2 diabetes. We are seeking adult volunteers, aged 18-65, who have body mass indices either in the lean range (18-25 kg/m2) or in the obesity range (30-45 kg/m2) but who do not have prediabetes or diabetes. Participants will undergo a…
Read More

Lowering Insulin Levels in Fatty Liver Disease

Condition: Endocrine & Metabolic Disease
Investigator: Joshua Cook, MD, PhD
Status: Currently Recruiting
We are conducting a research study on the effect of high insulin levels on the buildup of excessive liver fat ("fatty liver disease") in people at risk for type 2 diabetes. We are seeking adult volunteers, aged 18-70, who are overweight or obese with a body mass index of 27-50, and have been diagnosed with, or are at risk for, prediabetes.…
Read More

Body composition and metabolic manifestations of PCOS

Condition: Endocrine & Metabolic Disease
Investigator: Aviva Sopher, MD, MS
Status: Closed
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women ofreproductive age, affecting about 7% of this population when using the strictest diagnostic criteria and frequently presents in adolescence and young adulthood. Diagnostic features of PCOS includehyperandrogenism and ovulatory dysfunction. Additionally, both obese and…
Read More

A study for patients with Cushing's disease using study drug osilodrostat

Condition: Endocrine & Metabolic Disease / Cushing's Disease
Investigator: Pamela Freda, MD
Status: Closed
This study is for individuals who have Cushings disease and want to join voluntarily in this study to find out if a study drug called osilodrostat (LCI699) is safe and has beneficial effects in people who have Cushings disease. Cushings disease is a rare but debilitating disease. Cushings disease is caused by a benign tumor of the pituitary gland. The tumor…
Read More

Using New Tumor Markers in Blood (POMC, ACTH, and AgRP) to Diagnose and Track Cushing's Syndrome and Other Neuroendocrine Tumors

Condition: Endocrine & Metabolic Disease / Cushing's Disease
Investigator: Amanda Tsang
Status: Closed
The purpose of this study is to determine if measuring blood levels of proteins called POMC, AgRP, and chromogrannin A (CGA) can be used to diagnose and track tumor growth and recurrence in patients that have ACTH-dependent Cushing's syndrome, non-secreting pituitary tumors, and other neuroendocrine tumors. We invite you to participate if you have: a…
Read More

Metabolism Study

Condition: Endocrine & Metabolic Disease
Investigator: Judith Korner, MD
Status: Closed
The purpose of these studies is to gain an understanding of the mechanisms that promote weight loss and improved glucose control. The ultimate goal is to identify therapeutic pathways for obesity and diabetes as a way to optimize surgical procedures and discover novel non-surgical targets for safe and effective drug therapy. Participants with obesity will…
Read More

Temporary Insulin Resistance

Condition: Endocrine & Metabolic Disease
Investigator: Joshua Cook, MD, PhD
Status: Closed
We are recruiting healthy volunteers, aged 18-65, for a research study on the buildup of excessive liver fat ("fatty liver disease") in people with or at risk for type 2 diabetes because their bodies are resistant to the actions of the blood sugar-lowering hormone, insulin. To do this, we seek to induce temporary insulin resistance in 10-12…
Read More

Effect of Lowering Insulin Levels on Blood Sugar

Condition: Endocrine & Metabolic Disease
Investigator: Joshua Cook, MD, PhD
Status: Closed
We are conducting a research study on how much insulin is needed to control blood sugar in people at risk for type 2 diabetes. We are seeking adult volunteers, aged 18-65, who are overweight or obese with a body mass index of 25-45 and have been diagnosed with or are at risk for prediabetes. Participants will undergo two pancreatic clamp procedures…
Read More

A Study for Patients with Neuropathy Associated Pain to Compare study drugs Nortriptyline, Duloxetine, Pregabalin and Mexiletine

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
Peripheral Neuropathy is a result of nerve damage, which may cause weakness, numbness, tingling, and pain in your hands, feet, and other areas of your body. Over 20 million Americans are affected by peripheral neuropathy, most commonly caused by diabetes. In approximately 25-50% of all people with peripheral neuropathy, the cause is unknown. These cases…
Read More

Ectopic fat in PCOS

Condition: Endocrine & Metabolic Disease
Investigator: Aviva Sopher, MD, MS
Status: Closed
Polycystic ovary syndrome (PCOS) is a common disorder. Young women with PCOS have irregular or absence of menstruation and excessive acne and or hair on their bodies. They may have multiple cysts on their ovaries. Adolescents and women affected with PCOS are at risk of developing abnormalities in their blood including high fat, low HDL cholesterol (good…
Read More

Top-CSPN Study

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
This study is looking at using topiramate as a potential therapy for patients with cryptogenic sensory peripheral neuropathy. Patients who are randomized into the study will return to the clinic for follow up every 16 weeks. The total length of the study is 96 weeks.
Read More

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment with Subcutaneous Immunoglobulin

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to see how effective two doses of an investigational new drug called IgPro20 is when given subcutaneously (a shot given into the fat layer between the skin and the muscle) to treat CIDP in patients that still require IVIG and also to look at how safe the IgPro20 is for patients.
Read More

Study for patients with Amyloidsis (TTR) using an investigational drug, ALN-TTR02 for treatment

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to collect information about how patients with FAP respond to the study drug ALN-TTR02 over 18 months. This includes studying any potential improvements in FAP and any side effects that participants may have from the study drug. In addition, the study will examine how the body handles (distributes, break down, eliminates) the…
Read More

A study for patients with Cushing's disease using study drug LCI699

Condition: Endocrine & Metabolic Disease / Cushing's Disease
Investigator: Pamela Freda, MD
Status: Closed
The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease. Patients will be treated with the invesitigational drug LCI699 at doses up to 60 mg a day, and possibly for a short period of time with placebo. A placebo is a dummy drug ("pill") with no active medicine inside.
Read More

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
You are being considered to participate in this research study because you have type I or II diabetes with current treatment control and, you are experiencing painful diabetic peripheral neuropathy (DPN) in both lower extremities legs.The specific events that result in painful diabetic peripheral neuropathy are not well understood, but high blood sugar,…
Read More

A study for patients with acromegaly using study drug Octreotide

Condition: Endocrine & Metabolic Disease
Investigator: Pamela Freda, MD
Status: Closed
This study is for patients who have been diagnosed with acromegaly and have been treated with the injectable medications ocreotide or lanreotide for at least 6 months. You should have had the same dose for at least 4 months, and be adequately controlled. The purpose of this study is to compare the safety and effectiveness of an investigational new drug…
Read More

Study for treating patients with neuropathy using study drug fingolimod

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of study drug, fingolimod taken daily compared with a placebo (does not contain active medication) on delaying disability progression in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study will consist of 3 periods: a Screening Period (lasting for up to 45…
Read More

A Study to Assess the Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
Subjects with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) will be enrolled in the study and Intravenous Immunoglobulin (IVIg) will be given to eligible subjects on the study. CIDP is a chronic inflammatory condition that causes the immune system to attack the nerves. IVIg is one common treatment for CIDP. IVIG is a blood product that is…
Read More

Study for individuals who have had gastric bypass surgery at least one year prior and have type 2 diabetes.

Condition: Endocrine & Metabolic Disease
Investigator: Blandine Laferrere, MD, PhD
Status: Closed
This is a research study for subjects who have had gastric bypass surgery at least one year ago, and currently have type 2 diabetes. This study is looking at the treatment of diabetes after gastric bypass surgery. About 40% of patients do not experience diabetes remission after gastric bypass surgery. Of the patients who initially go into remission, about…
Read More

Study of patients with neuropathy using study drug, ISIS TTR Rx

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ISIS TTR Rx given for 65 weeks in patients with Familial Amyloid Polyneuropathy (FAP). The purpose of this study is to determine if ISIS 420915 can help people with mild or moderate FAP. To be in this study you must have FAP and be able to walk without help or walk with using only one cane.
Read More

A Study to Assess the Clinical and Biological Predictors of Disease Course in Patients with Guillain-Barre Syndrome

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
International GBS Outcome Study (IGOS) is a study of the Inflammatory Neuropathy Consortium (INC) and Peripheral Nerve Society (PNS) on disease course and outcome in Guillain-Barr syndrome (GBS). Guillian Barre syndrome is an autoimmune disorder affecting the peripheral nervous system, leading to paralysis and potential fatality if it progresses to involve…
Read More

A Study for Charcot-Marie-Tooth type 1A Patients to Compare 2 doses of PXT3003 vs. a Placebo

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
Charcot-Marie-Tooth type 1A (CMT1A) disease is a rare, slowly progressing and debilitating hereditary condition commonly causing weakness of muscles in the feet and lower parts of the legs. There is currently no approved drug to cure CMT1A disease, and the available treatments commonly target the pain and inflammation associated with the disease. In order…
Read More

A study for adults with growth hormone deficiency using study drug NNC0195-0092

Condition: Endocrine & Metabolic Disease / Growth Hormone Deficiency
Investigator: Pamela Freda, MD
Status: Closed
The purpose of this study is to investigate how well weekly injections of the growth hormone drug NNC0195-0092 works in adults with growth hormone deficiency. Growth hormone deficiency is a disorder that involves the pituitary gland (a small gland located at the base of the brain). The gland produces growth hormone and other hormones (chemical messengers of…
Read More

A Study of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (MyCIDPchoice)

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
We are doing this study to find out if the research drug known as Rozanolixizumab can have additional benefit for people who are already receiving IVIG( Intravenous Immune Globulin) treatment for CIDP, and to have further safety evaluation of the research drug as well. If you choose to be part of this research study, the following procedures will occur:…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science